Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInventory AverageInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Unicycive Therapeutics (UNCY) Enterprise Value (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Enterprise Value readings, the most recent being -$26.1 million for Q4 2024.

  • On a quarterly basis, Enterprise Value fell 169.48% to -$26.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$26.1 million, a 169.48% decrease, with the full-year FY2024 number at -$26.1 million, down 169.48% from a year prior.
  • Enterprise Value hit -$26.1 million in Q4 2024 for Unicycive Therapeutics, up from -$32.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$455000.0 in Q4 2022 to a low of -$48.9 million in Q1 2024.
  • Median Enterprise Value over the past 4 years was -$16.6 million (2021), compared with a mean of -$20.4 million.
  • Biggest five-year swings in Enterprise Value: surged 97.26% in 2022 and later crashed 2032.09% in 2023.
  • Unicycive Therapeutics' Enterprise Value stood at -$16.6 million in 2021, then surged by 97.26% to -$455000.0 in 2022, then crashed by 2032.09% to -$9.7 million in 2023, then plummeted by 169.48% to -$26.1 million in 2024.
  • The last three reported values for Enterprise Value were -$26.1 million (Q4 2024), -$32.3 million (Q3 2024), and -$41.8 million (Q2 2024) per Business Quant data.